Nextbiomedical Co (XKRX:389650) Research & Development: ₩8,033 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:389650 Nextbiomedical Co Ltd XKRX:389650
38 GF Score
Price ₩33,550.00
! 1 Warning Sign
View Full Analysis

What is Nextbiomedical Co Research & Development?

Nextbiomedical Co XKRX:389650 +1.82% 38 Research & Development is ₩8,033 Mil as of Jun. 2026. GuruFocus rates XKRX:389650 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nextbiomedical Co's Research & Development for the three months ended in Jun. 2026 was ₩2,089 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ₩8,033 Mil.

Nextbiomedical Co  (XKRX:389650) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nextbiomedical Co Research & Development Related Terms

Nextbiomedical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Nextbiomedical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextbiomedical Co Research & Development Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 3,245.05 3,578.84 4,782.97 6,622.40 7,581.19

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,708.12 1,790.49 2,070.04 2,083.82 2,088.72
XKRX:389650
38GF Score
Nextbiomedical Co Ltd XKRX:389650
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextbiomedical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩8,033 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₩8,033 Mil mean?
Nextbiomedical Co (XKRX:389650) has a Research & Development of ₩8,033 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nextbiomedical Co and its competitors.
Is Nextbiomedical Co's Research & Development too high?
Nextbiomedical Co's current Research & Development is ₩8,033 Mil. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's Research & Development compare to VRTX and REGN?
Nextbiomedical Co's Research & Development of ₩8,033 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nextbiomedical Co and its competitors. Nextbiomedical Co's current Research & Development is ₩8,033 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current Research & Development of ₩8,033 Mil. The current Research & Development is ₩8,033 Mil. Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current Research & Development is ₩8,033 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nextbiomedical Co Business Description

Address Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score

Get the complete analysis for XKRX:389650

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩33,550.00
Price